Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOKGet Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 31,200 shares, a drop of 28.9% from the February 13th total of 43,900 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average daily volume of 18,400 shares, the days-to-cover ratio is presently 1.7 days.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in Evoke Pharma, Inc. (NASDAQ:EVOKFree Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Evoke Pharma Stock Down 10.2 %

Shares of EVOK stock traded down $0.39 on Monday, hitting $3.43. The stock had a trading volume of 48,202 shares, compared to its average volume of 119,644. The business has a 50 day moving average price of $4.53 and a 200 day moving average price of $4.71. The company has a market cap of $5.10 million, a PE ratio of -0.31 and a beta of 0.12. Evoke Pharma has a one year low of $3.33 and a one year high of $12.32.

Evoke Pharma (NASDAQ:EVOKGet Free Report) last released its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.24). The firm had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evoke Pharma in a report on Wednesday, March 12th. They issued a “sell” rating for the company.

Read Our Latest Report on EVOK

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Featured Articles

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.